Abstract
Evidence-based medicine favours randomised controlled trials to limit bias and establish the effects of a treatment with statistical rigour. However, the controlled conditions and careful patient selection of randomised trials may produce results that cannot be generalised to a more diverse patient population in clinical practice. Therefore, there is growing recognition of the importance of supplementing randomised trial data with real-world evidence. Micronised purified flavonoid fraction has been investigated in several large-scale real-world studies, including the RELIEF and DECIDE studies, each of which included more than 1000 patients with chronic venous disease. These studies demonstrated a significant reduction in the prevalence and severity of chronic venous disease symptoms, and an improvement in quality of life. The chronic VEnous dIsorders maNagement and treatment effectivenesS evaluaTion in chronic vEnous disease, an international Program (VEINSTEP) study (NCT04574375), is currently underway in more than 6000 patients with chronic venous disease in nine countries. Preliminary data from one country (Morocco) indicate that chronic venous disease drug treatment, which was micronised purified flavonoid fraction in 75.7% of patients, was associated with a statistically significantly reduction in symptoms and improved quality of life. The overall results are awaited with interest. International chronic venous disease guidelines grade the evidence for micronised purified flavonoid fraction highly, as the benefits of micronised purified flavonoid fraction have been proven in randomised clinical trials and meta-analyses. Real-world studies demonstrate that the randomised evidence for micronised purified flavonoid fraction is generalisable to a clinical practice setting. Treatment decisions in chronic venous disease should consider evidence-based recommendations, including real-world data, as well as patient goals of symptom relief, functional improvement and/or better quality of life.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Evidence from real-world studies can be used to complement data obtained from randomised controlled trials and to provide support for guideline recommendations. |
Several large-scale real-world studies have demonstrated the effectiveness of micronised purified flavonoid fraction in the management of chronic venous disease. |
The ongoing multinational VEINSTEP study (chronic VEnous dIsorders maNagement and treatment effectivenesS evaluaTion in chronic vEnous disease, an international Program; NCT04574375) will provide further evidence of the effectiveness of conservative treatment (including venoactive drugs, such as micronised purified flavonoid fraction) for chronic venous disease in a real-world setting. |
1 Introduction
Chronic venous disease (CVD) is a very common medical problem. Although estimates vary, studies undertaken in a general practice setting suggest that between 45 and 60% of adults have CVD [1,2,3]. Global prevalence estimates range from 45.6 to 83.6%, with most patients having early-stage disease according to the Clinical, Etiological, Anatomical and Pathophysiological (CEAP) classification system [4]. A meta-analysis of global prevalence estimates indicate the prevalence by CEAP class to be 9% for C0s, 26% for C1, 19% for C2, 8% for C3, 5% for C4, 1% for C5 and 0.42% for C6 [4]. Therefore, most physicians will encounter patients with CVD on a regular basis and should be aware of the impact and management of this condition.
The aim of this article is to describe real-world evidence on the use of micronised purified flavonoid fraction (MPFF) for the treatment of CVD, including what we can expect to learn from the soon-to-be-completed VEINSTEP (chronic VEnous dIsorders maNagement and treatment effectivenesS evaluaTion in chronic vEnous disease, an international Program) study. The review also addresses how this research can be applied in clinical practice and how best to support patients with CVD.
2 Real-World Data with MPFF
Micronised purified flavonoid fraction has been studied in a number of large-scale real-world studies that included more than 1000 patients, including the international RELIEF study [5] and the French DECIDE study [6].
2.1 RELIEF Study
The Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids (RELIEF) study was conducted among 5052 patients with CEAP class C0 to C4 CVD in 23 countries over 2 years [5]. Patients were stratified into those with (43%) or without (57%) venous reflux, and treated with MPFF 1000 mg/day for 6 months. Every 2 months, patients were evaluated for symptoms (rated on a 4-point scale from 0 [absent] to 3 [severe]), pain (rated on a 10-cm visual analogue scale), oedema (rated by leg circumference) and quality of life (QoL; rated using the validated 20-item Chronic Venous Insufficiency Quality of Life Questionnaire [CIVIQ-20]).
After 6 months of treatment with MPFF, there were statistically significant reductions in symptoms of leg heaviness, sensation of swelling, cramps, and pain, as well as a significant reduction in the severity of oedema, in the overall group and in the subgroups of patients with or without reflux (all p = 0.0001). There was also a statistically significant reduction in the number of patients with CEAP class 3 or 4 CVD and an increase in those with C0 to C2 classes (p < 0.001), in both subgroups and in the overall study population. Using the global index of the CIVIQ-20, patients without reflux had better QoL throughout than those with reflux, but both groups had statistically significantly better QoL after 6 months of MPFF treatment compared with baseline (p = 0.0001 for both) [5].
2.2 DECIDE Study
The DECIDE study was conducted at 1323 general practices in France, and enrolled 13,131 patients with suspected CVD [6]. Although physicians were not asked to rate the patient’s CEAP class in this study, all patients were considered to fall into class C0s, C1s, C2s or C3s, based on their symptomatology. The principal aim of this study was to evaluate the use of a CVD symptom checklist in primary care, but a secondary aim was to evaluate the effects of treatment on QoL, using the CIVIQ-20 questionnaire, at the next follow-up visit. Of the 9345 treated patients with follow-up data, 8834 (94.5%) received MPFF 500 mg/day and 511 (5.5%) received another venoactive drug. Follow-up was a median of 63 days after starting treatment.
Treatment with MPFF markedly reduced the prevalence of CVD symptoms: heaviness by 25%, sensation of swelling by 48%, leg pain by 57%, night cramps by 61% and ‘pins and needles’ by 58% [6]. Overall, 7103 patients were included in the comparison of CIVIQ-20 scores between baseline and follow-up. All dimensions of QoL improved with CVD treatment, with the greatest improvement seen in the pain domain. The CIVIQ global score for overall QoL increased by a mean of 15.8 in patients receiving MPFF, which was statistically significantly greater than the mean increase of 10.3 in patients who received another type of venoactive drug (p < 0.001).
3 VEINSTEP Study
The chronic VEnous dIsorders maNagement and treatment effectivenesS evaluaTion in chronic vEnous disease, an international Program (VEINSTEP) study (NCT04574375) is currently assessing the effectiveness of conservative treatment for CVD in a real-world setting (Table 1). This observational study is being conducted in nine countries, Costa Rica, China, Dominican Republic, Honduras, Mexico, Morocco, Panama, Romania and Ukraine, and has enrolled 6419 participants. Eligible patients are adults who present spontaneously or are referred for symptomatic CVD that does not require surgical intervention and who are not receiving treatment for CVD, including venoactive drugs or compression stockings. No specific intervention is prescribed in this study, and physicians can prescribe whatever pharmacological or nonpharmacological treatment they think is appropriate based on their usual clinical practice [7].
VEINSTEP has four primary endpoints: (1) global leg symptom severity measured on a 4-point visual analogue scale; (2) global improvement using the Patient Global Impression of Change scale and time to improvement; (3) disease severity measured by the Venous Clinical Severity Score; and (4) QoL measured using CIVIQ-14. Follow-up is for 8 weeks, but the primary endpoints are measured at week 4.
To date, the complete results from the VEINSTEP study have not yet been published, but data are available from the Moroccan population (n = 3425) [7]. This subgroup had a mean age of 49.5 years and included 2845 female individuals (83.1%). Most patients in the Moroccan VEINSTEP population had class C2 (n = 1084 [31.6%]) or C3 (n = 1193 [34.8%]) CVD. Treatment included a venoactive drug in 98.9% of patients, most commonly MPFF (75.7%). Other venoactive drugs prescribed were diosmin (21.5%), Ruscus extracts (1.2%) and proanthocyanidins (1.1%). Other treatments prescribed included analgesics, topical therapies and compression.
Treatment that included venoactive drugs was associated with a statistically significant reduction in symptom severity between baseline and week 4 (p < 0.01). The greatest impact of treatment was on pain, heaviness, cramps and swelling, with reductions of 46–57%; the impact on paraesthesia, itching and burning was comparatively lower (27–39%) but still statistically significant [7]. Venoactive drug treatment, either alone or in combination with compression or topical therapy, was also associated with a statistically significant improvement across all three domains of QoL (pain, physical, psychological; p ≤ 0.001). Irrespective of treatment, 97.8% of patients reported an improvement on the Patient Global Impression of Change scale at week 4 and 98.6% at week 8, and 88% of Moroccan patients were satisfied or very satisfied with their treatment [7]. The overall results from the VEINSTEP study are awaited with interest and are expected to be published in the spring of 2023.
4 Application of Real-World Evidence in Clinical Practice
Evidence-based medicine principles were developed to support treatment decision making based on research-based evidence rather than on intuition, clinical experience or scientific rationale [8]. As a result, treatment guidelines now include information on the quality of the evidence to support their recommendations, with the highest quality evidence considered to come from randomised controlled trials, meta-analyses and systematic reviews [9]. These studies minimise bias and, therefore, provide rigorous evidence of a treatment’s efficacy [10]. Nevertheless, with carefully selected patient populations and an idealised setting, randomised trials may produce results that cannot be generalised to a more diverse population in clinical practice [11]. As a result, there is growing recognition of the importance of supplementing randomised trial data with real-world evidence to support clinical and regulatory decision making [11, 12].
The major international guidelines for CVD give MPFF the highest quality of evidence grading for its use in relieving symptoms of CVD, and is the only venoactive drug cited in guidelines as improving QoL [13, 14]. A summary of the evidence used in the 2018 guidelines (updated in 2020) from the European Venous Forum, International Union of Angiology, Cardiovascular Disease Educational and Research Trust (UK) and the Union Internationale de Phlébologie is shown in Table 2 [14, 15]. The quality rating of the MPFF recommendation reflects the weight of evidence derived from randomised controlled trials and meta-analyses.
Real-world evidence is subject to potential confounders, and on its own may not be a reliable indicator for treatment efficacy [10]. This may be especially true when assessing subjective symptoms in the non-blinded setting of an observational study [10]. Therefore, a more rational approach to the assessment of treatment effects is to consider the ‘totality of evidence’ synthesising data from both randomised and non-randomised studies [16].
The real-world data described here are directionally consistent with the results of randomised clinical trials and provide evidential support for the guideline recommendations in a real-world clinical practice setting. In addition, real-world data also show that the effects of CVD treatment on subjective symptom severity are correlated with objective parameters of disease severity, including ankle circumference [17] and the presence of detectable reflux [18], providing additional support for a reliable treatment effect.
Finally, it is important for physicians to remember that their most important role is to relieve the patient’s suffering. To do this, they must understand the aspects of CVD that are important to the patient. Therefore, while the first question in the consultation usually elicits the reason the patient has sought medical treatment (e.g. “what brings you here today?”), the second question should always be “what bothers you most about your condition?” Only when we understand what the patient wants most from treatment (symptom relief, cosmetic improvement, increased limb mobility/function, more restful sleep) can we select the most appropriate course of treatment.
5 Conclusions
The weight of evidence from randomised controlled trials, and increasingly from real-world studies, demonstrates both the efficacy and effectiveness of MPFF in the treatment of CVD, for relieving symptoms and improving QoL, and this is reflected in international guidelines.
References
Jawien A, Grzela T, Ochwat A. Prevalence of chronic venous insufficiency in men and women in Poland: multicentre cross-sectional study in 40,095 patients. Phlebology. 2003;18(3):110–22. https://doi.org/10.1258/0268355033223813.
Vuylsteke ME, Thomis S, Guillaume G, Modliszewski ML, Weides N, Staelens I. Epidemiological study on chronic venous disease in Belgium and Luxembourg: prevalence, risk factors, and symptomatology. Eur J Vasc Endovasc Surg. 2015;49(4):432–9. https://doi.org/10.1016/j.ejvs.2014.12.031.
Zahariev T, Anastassov V, Girov K, et al. Prevalence of primary chronic venous disease: the Bulgarian experience. Int Angiol. 2009;28(4):303–10.
Salim S, Machin M, Patterson BO, Onida S, Davies AH. Global epidemiology of chronic venous disease: a systematic review with pooled prevalence analysis. Ann Surg. 2021;274(6):971–6. https://doi.org/10.1097/SLA.0000000000004631.
Jantet G. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids. Angiology. 2002;53(3):245–56. https://doi.org/10.1177/000331970205300301.
Pitsch F. Results of the DECIDE survey: appraisal of the predictive value for chronic venous disease of a symptom checklist. Phlebolymphology. 2011;18(3):140–8.
Zoubida TM, Ulloa JH. VEIN STEP: Chronic VEnous dIsorders maNagement and treatment effectiveness evaluation in chronic venous disease, an international observational prospective study: results from Morocco. Phlebolymphology. 2021;28(2):68–78.
Evidence-Based Medicine Working Group. Evidence-based medicine: a new approach to teaching the practice of medicine. JAMA. 1992;268(17):2420–5. https://doi.org/10.1001/jama.1992.03490170092032.
Mandell BF. Evidence-based medicine and clinical guidelines. MSD manual. Professional version. 2021. https://www.msdmanuals.com/en-nz/professional/special-subjects/clinical-decision-making/evidence-based-medicine-and-clinical-guidelines. Accessed 26 Aug 2022.
Collins R, Bowman L, Landray M, Peto R. The magic of randomization versus the myth of real-world evidence. N Engl J Med. 2020;382(7):674–8. https://doi.org/10.1056/NEJMsb1901642.
Dreyer NA, Hall M, Christian JB. Modernizing regulatory evidence with trials and real-world studies. Ther Innov Regul Sci. 2020;54(5):1112–5. https://doi.org/10.1007/s43441-020-00131-5.
US Food and Drug Administration. Real-world evidence. 2022. https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence. Accessed 25 Aug 2022.
de Maeseneer MG, Kakkos SK, Aherne T, et al. Editor’s choice: European Society for Vascular Surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs. Eur J Vasc Endovasc Surg. 2022;63(2):184–267. https://doi.org/10.1016/j.ejvs.2021.12.024.
Nicolaides A, Kakkos S, Baekgaard N, et al. Management of chronic venous disorders of the lower limbs: guidelines according to scientific evidence. Part I. Int Angiol. 2018;37(3):181–254. https://doi.org/10.23736/S0392-9590.18.03999-8.
Nicolaides A, Kakkos S, Baekgaard N, et al. Management of chronic venous disorders of the lower limbs: guidelines according to scientific evidence. Part II. Int Angiol. 2020;39(3):175–240. https://doi.org/10.23736/S0392-9590.20.04388-6.
Eichler HG, Pignatti F, Schwarzer-Daum B, et al. Randomized controlled trials versus real world evidence: neither magic nor myth. Clin Pharmacol Ther. 2021;109(5):1212–8. https://doi.org/10.1002/cpt.2083.
Guex JJ, Enrici E, Boussetta S, Avril L, Lis C, Taieb C. Correlations between ankle circumference, symptoms, and quality of life demonstrate the clinical relevance of minimal leg swelling reduction: results of a study in 1,036 Argentinean patients. Dermatol Surg. 2008;34(12):1666–75. https://doi.org/10.1111/j.1524-4725.2008.34344.x.
Tsukanov YT, Tsukanov AY. Diagnosis and treatment of situational great saphenous vein reflux in daily medical practice. Phlebolymphology. 2017;24(3):144–51.
Acknowledgements
We thank Catherine Rees who wrote the first draft on behalf of Springer Healthcare Communications. This medical writing assistance was funded by Servier.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure statement
This article has been published as a part of a journal supplement wholly funded by Servier.
Funding
This article is based on a presentation given during a symposium funded by Servier.
Conflicts of interest
Jorge H. Ulloa is a recipient of a research/educational grant from Servier Laboratories. He received an honorarium from Servier for his participation in the symposium, and has other no conflicts of interest to declare.
Ethics approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Availability of data and material
Not applicable.
Code availability
Not applicable.
Authors’ contributions
JHU contributed to the conception, drafts and final version of this article, and gave approval of the version to be published.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Ulloa, J.H. Optimising Decision Making in Chronic Venous Disease Management with Micronised Purified Flavonoid Fraction. Clin Drug Investig 43 (Suppl 1), 15–19 (2023). https://doi.org/10.1007/s40261-023-01263-w
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40261-023-01263-w